Aventis Pharma S.a.

Rhone-poulenc Rorer S.a.

Aventis Pharmaceuticals Inc.

Aventis Pharmaceuticals Products Inc.

Nicolas Duverger

Patrice Denefle

Patrick Benoit

Alan Thomas Remaley

Cendrine Lemoine

Catherine Prades

Edward M Rubin

Gerd Assmann

Louis-Marie Houdebine

Harald Funke

Marie-Françoise Rosier-Montus

Bryan H Brewer

Celine Viglietta

Eric Bruckert

Jean-Charles Fruchart

G&eacute;rald Luc

G&eacute;rard Turpin

Laurent Naudin

Louis Marie Houdebine

Sylvia Santamarina-Fojo

Steven D Hughes

Florence Emmanuel

Didier Rouy

The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis. The invention also relates to nucleotide constructs comprising a polynucleotide which encodes a polypeptide or a nucleic acid of interest, placed under the control a regulatory nucleic acid for the ABC1 gene. The invention also relates to recombinant vectors, transformed host cells and nonhuman transgenic mammals comprising a nucleic acid which regulates the transcription of the ABC1 gene or an abovementioned nucleotide construct, as well as methods for screening molecules or substances which are capable of modifying the activity of the regulatory nucleic acid for the ABC1 gene.

Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses

A transgenic rabbit which has in its genomic DNA sequences that encode apolipoprotein (a) and apolipoprotein B polypeptides which are capable of combining to produce lipoprotein (a), a process for creating such a rabbit, and the use of the rabbit to identify compounds which are effective in the treatment of human diseases which are associated with, induced and/or exacerbated by Lp(a) expression.

Transgenic rabbit that expresses a functional human lipoprotein (a)

The present invention relates to variants of the human apolipoproteine A-I comprising a cystein in position 151, the corresponding nucleic acids and the vectors containing them. It also relates to pharmaceutical compositions comprising said elements and their utilization, particularly in genic therapy.

Variants of apolipoprotein A-I

Dyslipoproteinaemia-sensitized transgenic rabbit

Growing community of inventors

Paris, France

Nicolas Duverger